tbuckley/cabot-search huggingface dataset:
Sixty seconds on . . . nature immersion
Authors: Abi Rimmer
Journal: BMJ (2019)

Well, no, actually, we’re talking about a nature immersion course that is being run for GPs and GP trainees on Dartmoor in June next year,1 supported by the Royal College of General Practitioners.2 Hopefully it will be a bit warmer then.

GP Lucy Loveday (@drlucyloveday), who will be one of the course facilitators, explained that the course deliberately takes doctors out of an urban training room session and …
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Authors: Leonardo R. Brandão, Manuela Albisetti, Jacqueline Halton, Lisa Bomgaars, Elizabeth Chalmers, Lesley G. Mitchell, Ildar Nurmeev, Pavel Svirin, Tomas Kuhn, Ondrej Zapletal, Igor Tartakovsky, Monika Simetzberger, Fenglei Huang, Zhichao Sun, Jörg Kreuzer, Savion Gropper, Martina Brueckmann, Matteo Luciani
Journal: Blood (2019)
TCRbeta Gene Rearrangements for Detection and Monitoring of Minimal Residual Disease after Allogenic Stem-Cell Transplantation in Patients with Advanced Mycosis Fungoides and Sézary Syndrome.
Authors: Laura Corti, Giorgia Saporiti, Elisa Fermo, Emilio Berti, Luigia Venegoni, Giorgio Lambertenghi Deliliers, Francesco Onida
Journal: Blood (2008)
Structural and Functional Interactions of KCl Cotransport Proteins KCC1 and KCC3 in Sickle and Normal Erythrocyte Membranes
Authors: Mary Risinger, Jesse Rinehart, Scott Crable, Anna Ottlinger, Richard Winkelmann, Dao Pan, Christian Huebner, Patrick G. Gallagher, Clinton H. Joiner
Journal: Blood (2008)
Long-term outcome of patients randomized in the euro-lupus nephritis trial: Further evidence that a low-dose IV cyclophosphamide induction regimen achieves good results
Authors: Frédéric Houssiau, Jean-Pierre Cosyns, C. Vasconcelos, D. D'Cruz, G. Sebastiani, Enrique de Ramon Garrido, M. Danieli, Daniel Abramovicz, D. Blockmans, A. Cauli, H. Direskeneli, M. Galeazzi, Ahmet Gül, Y. Levy, P. Petera, R. Popovic, R. Petrovic, R. Sinico, R. Cattaneo, J. Font, Geneviève Depresseux, R. Cervera
Journal: Annals of the Rheumatic Diseases (2006)
High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML.
Authors: Mukta Arora, Stephen Spellman, Michael Haagenson, John P. Klein, Carolyn Hurley, George Selby, Joseph Antin, Nancy Kernan, Craig Kollman, Auayporn Nademanee, Daniel J. Weisdorf, Mary M. Horowitz, Philip McGlave, Effie Petersdorf
Journal: Blood (2007)
Differentiation Profiling of Marrow Stem Cells: A Megakaryopoietic Hotspot and the Continuum Model of Hematopoiesis.
Authors: Gerald A. Colvin, Dooner Gerri, Delia Demers, Shiela Pascual, Samuel Chung, Mark S. Dooner, Mehrdad Abedi, Peter J. Quesenberry
Journal: Blood (2005)
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation
Authors: Stephen Zewinger, Jochen Reiser, Vera Jankowski, Dalia Alansary, Eunsil Hahm, Sarah Triem, Mira Klug, Stefan J. Schunk, David Schmit, Rafael Kramann, Christina Körbel, Emmanuel Ampofo, Matthias W. Laschke, Simina-Ramona Selejan, Anna Paschen, Tobias Herter, Susanne Schuster, Günther Silbernagel, Martina Sester, Urban Sester, Gunter Aßmann, Robert Bals, Gerhard Kostner, Willi Jahnen-Dechent, Michael D. Menger, Lucia Rohrer, Winfried März, Michael Böhm, Joachim Jankowski, Manfred Kopf, Eicke Latz, Barbara A. Niemeyer, Danilo Fliser, Ulrich Laufs, Thimoteus Speer
Journal: Nature Immunology (2019)
Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model.
Authors: Steve D. Hughes, Ken Bannink, Cecile Krejsa, Mark Heipel, Becky Johnson, Rick Holly, P.V. Sivakumar, Katherine Henderson, Chris Clegg, Eric Sievers, Wayne Kindsvogel, Don Foster
Journal: Blood (2004)
Pancreatitis Preceding Acute Episodes of Thrombotic Thrombocytopenic Purpura: Report of Five Patients with a Systematic Review of Published Reports.
Authors: Karen K. Swisher, John T. Doan, Sara K. Vesely, Hau C. Kwaan, Benjamin Kim, Bernhard Lammle, Johanna Kremer Hovinga, James N. George
Journal: Blood (2006)
Micro/nano-bubble-assisted ultrasound to enhance the EPR effect and potential theranostic applications
Authors: Lei Duan, Li Yang, Juan Jin, Fang Yang, Dong Liu, Ke Hu, Qinxin Wang, Yuanbin Yue, Ning Gu
Journal: Theranostics (2019)

Drug delivery for tumor theranostics involves the extensive use of the enhanced permeability and retention (EPR) effect.Previously, various types of nanomedicines have been demonstrated to accumulate in solid tumors via the EPR effect.However, EPR is a highly variable phenomenon because of tumor heterogeneity, resulting in low drug delivery efficacy in clinical trials.Because ultrasonication using micro/nanobubbles as contrast agents can disrupt blood vessels and enhance the specific delivery of drugs, it is an effective approach to improve the EPR effect for the passive targeting of tumors.In this review, the basic thermal effect, acoustic streaming, and cavitation mechanisms of ultrasound, which are characteristics that can be utilized to enhance the EPR effect, are briefly introduced.Second, micro/nanobubble-enhanced ultrasound imaging is discussed to understand the validity and variability of the EPR effect.Third, because the tumor microenvironment is complicated owing to elevated interstitial fluid pressure and the deregulated extracellular matrix components, which may be unfavorable for the EPR effect, few new trends in smart bubble drug delivery systems, which may improve the accuracy of EPR-mediated passive drug targeting, are summarized.Finally, the challenging and major concerns that should be considered in the next generation of micro/nanobubble-contrast-enhanced ultrasound theranostics for EPR-mediated passive drug targeting are also discussed.
Abstract 18986: Mid-Term Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention With Subadventitial vs. Intraplaque Crossing: a Systematic Review and Meta-Analysis
Authors: Aris Karatasakis, Barbara A Danek, Judit Karacsonyi, Lorenzo Azzalini, Mauro Carlino, Stephane Rinfret, Minh Vo, Bavana V Rangan, M N Burke, Subhash Banerjee, Emmanouil S Brilakis
Journal: Circulation (2017)

Introduction: Some reports have demonstrated increased risk with subadventitial chronic total occlusion (CTO) crossing, whereas others suggest equipoise between subadventitial and intraplaque cross...
The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management
Authors: Enrica Marchi, Owen A. O’Connor
Journal: CA A Cancer Journal for Clinicians (2019)

Abstract Historical advances in the care of patients with non‐Hodgkin lymphoma (NHL) have been restricted largely to patients with B‐cell lymphoma. The peripheral T‐cell lymphomas (PTCLs), which are rare and heterogeneous in nature, have yet to experience the same degree of improvement in outcome over the past 20 to 30 years. It is estimated that there are approximately 80,000 and 14,000 cases, respectively, of NHL and Hodgkin lymphoma per year in the United States. As a subgroup of NHL, the PTCLs account for 6% to 10% of all cases of NHL, making them exceedingly rare. In addition, the World Health Organization 2017 classification describes 29 distinct subtypes of PTCL. This intrinsic diversity, coupled with its rarity, has stymied progress in the disease. In addition, most subtypes carry an inferior prognosis compared with their B‐cell counterparts, an outcome largely attributed to the fact that most treatment paradigms for patients with PTCL have been derived from B‐cell neoplasms, a radically different disease. In fact, the first drug ever approved for patients with PTCL was approved only a decade ago. The plethora of recent drug approvals in PTCL, coupled with a deeper understanding of the molecular pathogenesis of the disease, has stimulated the field to pursue new avenues of research that are now largely predicated on the development of novel, targeted small molecules, which include a host of epigenetic modifiers and biologics. There is an expectation these advances may begin to favorably challenge the chemotherapy paradigms that have been used in the T‐cell malignancies.
Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.
Authors: John P. Leonard, Joseph D. Rosenblatt, Nancy L. Bartlett, Ajay Gopal, Anas Younes, David Fisher, Francine Foss, Andres Forero, Steven Bernstein, Bruce Cheson, Matthew H. Carabasi, R. Gregory Bociek, Bruce Hart, Michael McDonald
Journal: Blood (2004)
A Novel Heterologous Expression System for Characterization of Individual NADH-Cytochrome b5 Reductase Variants in Recessive Congenital Methemoglobinemia.
Authors: Melanie J. Percy, L. J. Crowley, C. A. Davis, J. Boudreaux, D. M. Layton, M. F. McMullin, T. R. Lappin, M. J. Barber
Journal: Blood (2005)
Beneficial effect of stopping smoking on future cardiac events in male smokers with previous myocardial infarction.
Authors: Isao Sato, Masayuki Nishida, Kohichi Okita, Hirotaka Nishijima, Shunichi Kojima, Naoya Matsumura, Hisakazu Yasuda
Journal: Circulation (1992)

We assessed the effect of stopping smoking on future cardiac events (cardiac death and non-fatal myocardial infarction (MI)) in 90 male smokers with previous MI by a prospective follow-up study. At the time of enrollment, the patients were divided into 2 groups according to their current smoking status (Group A: those who had stopped smoking (n=60), and Group B: those who were still smoking (n=30)). Follow-up was performed prospectively by annual postal questionnaires. During the mean follow-up period of 3.1 ± 1.4 years, 13 cardiac events (11 cardiac deaths and 2 cases of non-fatal MI) occurred in the 87 evaluable patients. The cardiac event rates in Groups A and B were 8.5% and 28.6%, respectively, and the relative risk was 3.4 (Group A vs B, p<0.05) by univariate analysis. The relative risk using multivariate analysis (Cox) was also statistically significant (3.1, p<0.05). HDL-cholesterol was significantly lower in Group B than in Group A, but other coronary risk factors apart from smoking were not significantly different between the two groups. At the end of the follow-up period, 89.8% of the patients in Group A remained nonsmokers and 21% of the patients in Group B had stopped smoking. Conclusion: Stopping smoking significantly reduced the risk of future cardiac events in male smokers with previous MI. This prospective follow-up study demonstrated that a significant reduction in the risk of future cardiac events could be achieved by stopping smoking in this group of patients.
Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study
Authors: Samah Hayek, Todd M. Gibson, Wendy M. Leisenring, Jennifer L. Guida, Maria Monica Gramatges, Philip J. Lupo, Rebecca M. Howell, Kevin C. Oeffinger, Smita Bhatia, Kim Edelstein, Melissa M. Hudson, Leslie L. Robison, Paul C. Nathan, Yutaka Yasui, Kevin R. Krull, Gregory T. Armstrong, Kirsten K. Ness
Journal: Journal of Clinical Oncology (2019)

PURPOSE To estimate the prevalence of frailty among childhood cancer survivors and to determine the direct and indirect effects of treatment exposures, lifestyle factors, and severe, disabling, and life-threatening chronic condition on frailty. METHODS Childhood cancer survivors (≥ 5 years since diagnosis), treated between 1970 and 1999 when &lt; 21 years old (n = 10,899; mean age, 37.6 ± 9.4 years; 48% male, 86% white) and siblings were included (n = 2,097; mean age, 42.9 ± 9.4 years). Frailty was defined as ≥ 3 of the following: low lean mass, exhaustion, low energy expenditure, walking limitations, and weakness. Generalized linear models were used to evaluate direct and indirect associations between frailty and treatment exposures, sociodemographic characteristics, lifestyle factors, and chronic condition. RESULTS The overall prevalence of frailty among survivors was 3 times higher compared with siblings (6.4%; 95% CI, 4.1% to 8.7%; v 2.2%; 95% CI, 1.2% to 3.2%). Survivors of CNS tumors (9.5%; 95% CI, 5.2% to 13.8%) and bone tumors (8.1%; 95% CI, 5.1% to 11.1%) had the highest prevalence of frailty. Survivors exposed to cranial radiation, pelvic radiation ≥ 34 Gy, abdominal radiation &gt; 40 Gy, cisplatin ≥ 600 mg/m 2 , amputation, or lung surgery had increased risk for frailty. These associations were partially but not completely attenuated when sociodemographic characteristics, lifestyle factors, and chronic conditions were added to multivariable models. Cranial radiation (prevalence ratio [PR], 1.47; 95% CI, 1.20 to 1.76), pelvic radiation ≥ 34 Gy (PR, 1.46; 95% CI, 1.01 to 2.11), and lung surgery (PR, 1.75; 95% CI, 1.28 to 2.38) remained significant after sociodemographic, lifestyle, and chronic conditions were accounted for. CONCLUSION Childhood cancer survivors reported a higher prevalence of frailty compared with siblings. Radiation and lung surgery exposures were associated with increased risk for frailty. Interventions to prevent, delay onset, or remediate chronic disease and/or promote healthy lifestyle are needed to decrease the prevalence of frailty and preserve function in this at-risk population.
Exercise Intervention to Improve Functional Capacity in Older Adults After Acute Coronary Syndrome
Authors: Gianluca Campo, Elisabetta Tonet, Giorgio Chiaranda, Gianluigi Sella, Elisa Maietti, Gianni Mazzoni, Simone Biscaglia, Rita Pavasini, Jonathan Myers, Giovanni Grazzi
Journal: Journal of the American College of Cardiology (2019)
Bcr-Abl Promotes CML Cell Proliferation through the Suppression of PHLPP Expression.
Authors: Isao Hirano, Satoki Nakamura, Daisuke Yokota, Takaaki Ono, Kazuyuki Shigeno, Shinya Fujisawa, Kaori Shinjo, Kazunori Ohnishi
Journal: Blood (2008)
BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact
Authors: Shady Adnan Awad, Helena Hohtari, Komal Kumar Javarappa, Tania Brandstoetter, Daehong Kim, Swapnil Potdar, Caroline A Heckman, Soili Kytölä, Kimmo Porkka, Eszter Doma, Veronika Sexl, Matti Kankainen, Satu Mustjoki
Journal: Blood (2019)
Diabetes INSIDE: Improving Population HbA1c Testing and Targets in Primary Care With a Quality Initiative
Authors: Roy E. Furman, Timothy S. Harlan, Lesley LeBlanc, Elise C. Furman, Greg Liptak, Vivian A. Fonseca
Journal: Diabetes Care (2019)

OBJECTIVE To improve outcomes of patients with adult type 2 diabetes by decreasing HbA1c undertesting, reducing the proportion of patients with poor glycemic control, and lowering mean HbA1c levels using a quality improvement (QI) program. RESEARCH DESIGN AND METHODS Six years of outpatient electronic health record (EHR) data were analyzed for care gaps before and 2 years after implementing a QI initiative in an urban academic medical center. QI strategies included 1) individual provider and departmental outcome reports, 2) patient outreach programs to address timely follow-up care, 3) a patient awareness campaign to improve understanding of achieving clinical goals, 4) improving EHR data capture to improve population monitoring, and 5) professional education. RESULTS Analysis (January 2010 to May 2018) of 7,798 patients from Tulane Medical Center (mean age 61 years, 57% female, 62% black, 97% insured) with 136,004 visits showed target improvements. A Cox proportional hazards model controlling for age, sex, race, and HbA1c level showed a statistically significant reduction in HbA1c undertesting &amp;gt;6 months (hazard ratio 1.20 ± 0.07). Statistical process control charts showed 15.5% relative improvement in the patient proportion with HbA1c &amp;gt;9% (75 mmol/mol) from 13% to 11% (P &amp;lt; 10−6) following QI interventions and a 2.1% improvement of population mean HbA1c from 7.4% (57 mmol/mol) to 7.2% (55 mmol/mol) (P &amp;lt; 10−6). CONCLUSIONS Multidisciplinary QI teams using EHR data to design interventions for providers and patients produced statistically significant improvements in both care process and clinical outcome goals.
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities.
Authors: Michele Cavo, Nicoletta Testoni, Carolina Terragna, Giulia Marzocchi, Sandra Durante, Renato Zambello, Chiara Nozzoli, Lucia Pantani, Paola Tacchetti, Luciano Masini, Michela Ceccolini, Paola Agostini, Elena Zamagni, Valerio De Stefano, Patrizia Tosi, Daniele Derudas, Laura Dessanti, Stelvio Ballanti, Salvatore Palmieri, Andrea Nozza, Gioacchino Catania, Jacopo Peccatori, Alfonso D’Arco, Pellegrino Musto, Mariella Grasso, Maria Caterina Pallotti, Silvana Pasini, Pier Paolo Fattori, Anna Baraldi, Delia Cangini, Filippo Ballerini, Alessandro Petrucci, Michele Baccarani
Journal: Blood (2008)
The Feasibility of High-Dose Dexamethasone (HD-DEX) in Idiopathic Thrombocytopenic Purpura (ITP) in Adults; a Multi-Center Study in Korea.
Authors: Yeo-Kyeoung Kim, Je-Jung Lee, Moo-Rim Park, Sung-Hwa Bae, Hyo Jung Kim, Seok Jung Kim, Deok-Hwan Yang, Byung Soo Kim, Hyeoung-Joon Kim, Chul Won Choi
Journal: Blood (2005)
Correlation between biopsy type and insufficient tissue availability for biomarker testing in five solid cancer types.
Authors: Pieter De Richter, Jackie Ilacqua
Journal: Journal of Clinical Oncology (2013)

e22136 Background: Limited tissue availability is a known barrier to conducting biomarker testing on cancer tissue specimens. It has been assumed that the frequency of insufficient tissue being available is correlated with type of tissue biopsy performed, but this has not previously been quantified across multiple cancer types. Methods: A panel of pathologists in the US (N=90) were asked to report on recent cancer tissues they prepared/handled for biomarker testing. The physicians were asked to report on the cancer type, biopsy method, molecular diagnostics tests conducted, and whether sufficient tissue was available for all requested tests. If insufficient tissue was available, they were asked to report on which tests they were unable to perform as a result. All data was collected through an online survey between August and November 2012. Results: In total, 99 breast cancer samples, 85 NSCLC samples, 60 CRC samples, 30 gastric cancer samples and 40 melanoma samples were reported on. Insufficient tissue was available in 5 (6%) of all NSCLC samples, 2 of which were obtained through fine needle aspirations (14% of all FNAs), a further 2 through core biopsies (5%), and a further 1 through a bronchoscopy (8%). Insufficient tissue was available in 1 (1%) of all breast cancer samples (core biopsy, 1% of all core biopsies), 1 (3%) of all melanoma samples (core biopsy, 13% of all core biopsies) and 1 (2%) of all CRC samples (core biopsy, 11% of all core biopsies). Conclusions: Insufficient cancer tissue for biomarker testing occurred across 4 out of 5 cancer types reported on, though was rare (&lt;5%) in cancers other than NSCLC. The majority of tissue samples in which insufficient tissue was present were acquired through core biopsies (67% of all cases) or FNAs (22% of all cases).
Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.
Authors: Kadri Altundag, Sercan Aksoy, Mehmet Ali Nahit Sendur, Emine Nilufer Guler, Ibrahim Halil Gullu, Yavuz Yasin Ozisik
Journal: Journal of Clinical Oncology (2013)

e11553 Background: Systemic chemotherapy is often ineffective due to the impermeability of the blood-brain barrier (BBB) and inherent chemoresistance of CNS metastases. There are limited data supporting the use of capecitabine in this setting. The aim of this study was to evaluate the effectiveness and toxicity of capecitabine in breast cancer patients with CNS metastasis. Methods: The records of all patients with HER-2 Negative breast cancer with CNS metastasis that treated with capecitabine monotherapy were evaluated. All patients recieved capecitabine at a dose of 2,500mg/m 2 /day for 14 days at 3 weeks intervals. Results: Fifty-eight female patients with a median age of 42 years (min-max; 20-68) were included in this retrospective analysis. The median time to brain metastasis was 3.1 years (min-max; 0.5-15.5). Thirty (51%) patients were hormone positive, and twenty-nine (49%) were triple-negative. Forty-seven (78%) patients recieved capecitabine as first line treatment after the CNS metastasis. Only 4 patients had undergone surgery for CNS metastasis, and all patients had recieved whole brain radiotherapy before the capecitabine treatment. Five (8.5%) patents were treated with cyberknife radiosurgery. There were 6 (10%) complete (2 patient had metastasectomy for brain metastasis), and 21 (36%) partial responses with 9 (15%) patients having stable disease. Progressive disease was observed in 16 (28%) patients. 6 patients were not evaluabled for radiological evaluation. Median progression free survival time was 5 months, and median overall survival was 8.6 months. Dose reduction was required due to adverse effects in 20 patients (24%). The most frequent side effect was the hand-food syndrome (HFS), which developed in 29 patients (50%). Forty-percent of them developed grade 3 HFS disease. Diarrhea occurred in 21% of the patients, nausea in 19% of the patients. Grade 3-4 myelosupression were developed in 15% of the patients. There was no treatment-related death. Conclusions: Capecitabine is effective and well tolerated in the treatment of breast cancer patients with CNS metastases. It is feasible options HER2 negative breast cancer patients especially with neurological deficits.
Vincristine (VCR) - Dexamethasone (DEXA) Pulses for Intermediate Risk (IR) Childhood Acute Lymphoblastic Leukemia (ALL) Treated with BFM Based Protocols: Results of the I-BFM-SG ALL IR 95 Study.
Authors: Valentino Conter, Maria Grazia Valsecchi, Daniela Silvestri, Myriam Campbell, Eduardo A. Dibar, Edina Magyarosy, Helmut Gadner, Jan Stary, Yves Benoit, Hansjoerg Riehm, Giuseppe Masera, Martin Schrappe
Journal: Blood (2005)
Abstract 15559: COR-ART: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose Modification Study to Evaluate Single Oral Doses of GBR-12909 for Conversion of Subjects With Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm
Authors: Howard C Dittrich, A J Camm, Gregory K Feld, Sergey P Golitsyn, Amos Katz, Peter R Kowey, Albert Waldo, Arthur M Brown
Journal: Circulation (2013)

Purpose: To evaluate the safety and efficacy of a single oral dose of GBR-12909 (GBR) compared to placebo (PBO) in a dose modification manner in subjects with recent onset symptomatic atrial fibril...